Interest Income Expense - Ryvu Therapeutics SA (WSE:RVU) - Alpha Spread
R

Ryvu Therapeutics SA
WSE:RVU

Watchlist Manager
Ryvu Therapeutics SA
WSE:RVU
Watchlist
Price: 54.2 PLN -0.18% Market Closed
Market Cap: 1.3B PLN
Have any thoughts about
Ryvu Therapeutics SA?
Write Note

Ryvu Therapeutics SA
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Ryvu Therapeutics SA
Interest Income Expense Peer Comparison

Comparables:
I
IGN
M
MDB
S
SLV

Competitive Interest Income Expense Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
R
Ryvu Therapeutics SA
WSE:RVU
Interest Income Expense
zł7.4m
CAGR 3-Years
4%
CAGR 5-Years
-21%
CAGR 10-Years
N/A
I
Inno-Gene SA
WSE:IGN
Interest Income Expense
-zł2.6m
CAGR 3-Years
N/A
CAGR 5-Years
-109%
CAGR 10-Years
-29%
M
Medicofarma Biotech SA
WSE:MDB
Interest Income Expense
-zł171.8k
CAGR 3-Years
-35%
CAGR 5-Years
-77%
CAGR 10-Years
N/A
S
Selvita SA
WSE:SLV
Interest Income Expense
-zł916k
CAGR 3-Years
36%
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Ryvu Therapeutics SA's Interest Income Expense?
Interest Income Expense
7.4m PLN

Based on the financial report for Mar 31, 2024, Ryvu Therapeutics SA's Interest Income Expense amounts to 7.4m PLN.

What is Ryvu Therapeutics SA's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
-21%

The average annual Interest Income Expense growth rates for Ryvu Therapeutics SA have been 4% over the past three years , -21% over the past five years .

Back to Top